Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,959 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president directly owned 23,305 shares of the company’s stock, valued at $7,226,414.40. The trade was a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, February 17th, Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $331.96, for a total transaction of $677,530.36.
• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70.
• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $18.21 during midday trading on Tuesday, reaching $332.61. 1,516,365 shares of the company were exchanged, compared to its average volume of 1,632,567. The stock has a market cap of $44.11 billion, a P/E ratio of 194.51 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a fifty day simple moving average of $372.67 and a 200 day simple moving average of $424.73. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.65) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. OFI Invest Asset Management raised its position in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 22 shares during the last quarter. Howard Capital Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 2.9% in the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 24 shares during the last quarter. Frank Rimerman Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.3% during the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC increased its position in Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 28 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Wells Fargo & Company reduced their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Jefferies Financial Group decreased their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $489.00 price target (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.